Dr. Reddy’s Laboratories (DRREDDY) Share Price Near 52-Week High After Stable Move
- November 18, 2026
- Posted by: Chaitanya Auti
- Category: News
Dr. Reddy’s Laboratories Share Price is at Rs 1,389, up 0.14% today, and trading near its 52-week high with a market capitalisation of Rs 1,15,267.47 crore. The move keeps Dr. Reddy’s Laboratories Share Price in focus for stock news, valuation and sector comparison.
Dr. Reddy’s Laboratories Share Price is trading at Rs 1,389, up 0.14% today, and sitting close to its 52-week high as of 18 November 2026 at 11:22 AM IST. The company’s market capitalisation stands at Rs 1,15,267.47 crore, placing the latest Dr. Reddy’s Laboratories Share Price move in a clear large-scale market context. The stock opened at Rs 1,384, touched Rs 1,390 and Rs 1,376.8 during the morning trade, and remained near the upper end of its daily band. According to latest Univest data, the price event is confirmed, but the information set does not establish a company-specific catalyst. That makes Dr. Reddy’s Laboratories Stock News relevant mainly for what the numbers show today rather than for any inferred reason.
Dr. Reddy’s Laboratories Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,389 |
| Previous Close | Rs 1,387 |
| Today's Move | +Rs 2 (+0.14%) |
| Open | Rs 1,384 |
| High | Rs 1,390 |
| Low | Rs 1,376.8 |
| Market Capitalisation | Rs 1,15,267.47 crore |
Dr. Reddy's Laboratories Ltd. (DRREDDY) traded at Rs 1,389 versus the previous close of Rs 1,387, a rise of 0.14%. The stock opened at Rs 1,384, reached a high of Rs 1,390 and touched a low of Rs 1,376.8.
Dr. Reddy’s Laboratories Share Price Today reflects a narrow early move, with the stock at Rs 1,389 against the previous close of Rs 1,387, a gain of Rs 2. The intraday range has been Rs 1,376.8 to Rs 1,390, while the open at Rs 1,384 placed the first trade just below the previous session’s reference level. Dr. Reddy’s Laboratories Share Price has therefore remained close to its one-year high while still trading inside the day’s range rather than outside it. For readers tracking Dr. Reddy’s Laboratories Share Price News, the key point is straightforward: the stock is near a yearly high, but the latest Univest figures show no separate explanation beyond the price event itself. That sets up the wider Dr. Reddy’s Laboratories Stock News discussion around fundamentals and sector context.
Why Dr. Reddy’s Laboratories Ltd. (DRREDDY) May Be Moving Today
According to recent news reports, Dr Reddy’s Laboratories may be moving in the context of HSBC maintaining a Buy view and raising its target price to Rs 1,525 after 2QFY27 operational performance met expectations. The same update says investor focus is now on management commentary around growth drivers and the execution of key pharmaceutical launches. This news flow coincides with Dr. Reddy’s Laboratories Share Price staying near its 52-week high, so Dr. Reddy’s Laboratories Share Price Today may be drawing added attention from readers following Dr. Reddy’s Laboratories Stock News and Dr. Reddy’s Laboratories Latest News. The report does not establish causation, but it does place Dr. Reddy’s Laboratories Share Price News alongside a clear broker update.
Dr. Reddy's Laboratories Ltd. (DRREDDY) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,15,267.47 crore |
| P/E Ratio | 41.38x |
| P/B Ratio | 2.99x |
| ROE | 11.69% |
| ROCE | 13.75% |
| EPS | Rs 33.52 |
| Book Value Per Share | Rs 464.6 |
| Dividend Yield | 0.58% |
Dr. Reddy's Laboratories Ltd. (DRREDDY) fundamental metrics show P/E 41.38x, P/B 2.99x, ROE 11.69%, ROCE 13.75%. These figures provide context only and are not a buy or sell signal.
Dr. Reddy’s Laboratories Ltd. has a market capitalisation of Rs 1,15,267.47 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 41.38x, P/B at 2.99x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.69% and ROCE of 13.75%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 33.52, book value per share of Rs 464.6, dividend yield of 0.58%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 26.36x, median ROE of 11.22%, median ROCE of 12.76%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 41.38x |
| Benchmark Median P/E | 26.36x |
| Benchmark Average P/E | 50.53x |
| Benchmark P/E Range | 0x to 1,425.63x |
| Company P/B Ratio | 2.99x |
| Benchmark Median P/B | 2.73x |
| Company ROE | 11.69% |
| Benchmark Median ROE | 11.22% |
| Company ROCE | 13.75% |
| Benchmark Median ROCE | 12.76% |
| Company Market Capitalisation | Rs 1,15,267.47 crore |
| Benchmark Median Market Cap | Rs 747.19 crore |
Dr. Reddy's Laboratories Ltd. (DRREDDY) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Dr. Reddy's Laboratories Ltd. (DRREDDY) has a P/E ratio of 41.38x, which is above the benchmark median of 26.36x, a difference of +56.98%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Dr. Reddy's Laboratories Ltd. (DRREDDY) has a ROE of 11.69%, which is above the benchmark median of 11.22%, a difference of +4.19%. Dr. Reddy's Laboratories Ltd. (DRREDDY) has a ROCE of 13.75%, which is above the benchmark median of 12.76%, a difference of +7.76%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Cipla Ltd. | CIPLA | 1,12,619.6 | 38.57 | 3.16 | 11.83 | 16 |
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,18,603.21 | 28.7 | 4.31 | 19.69 | 21.39 |
| Laurus Labs Ltd. | LAURUSLABS | 1,19,789.92 | 94.36 | 20.86 | 18.31 | 18.2 |
| Mankind Pharma Ltd. | MANKIND | 1,08,424.34 | 47.98 | 6.12 | 12.69 | 13.24 |
| Aurobindo Pharma Ltd. | AUROPHARMA | 1,02,877.57 | 25.85 | 2.62 | 9.93 | 12.76 |
Dr. Reddy's Laboratories Ltd. (DRREDDY) has a P/E ratio of 41.38x compared with the displayed peer median of 38.57x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.69% compares with a peer median of 12.69% across the companies shown in the table. ROCE stood at 13.75% versus the displayed peer median of 16%, providing a capital-efficiency comparison. Dr. Reddy's Laboratories Ltd. (DRREDDY) has a market capitalisation of Rs 1,15,267.47 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching Dr. Reddy’s Laboratories
- Dr. Reddy’s Laboratories Share Price is trading at Rs 1,389, near its 52-week high and above the previous close of Rs 1,387.
- The market capitalisation is Rs 1,15,267.47 crore, keeping Dr. Reddy’s Laboratories Share Price in a large market-cap context.
- The P/E ratio is 41.38, above the same-industry median of 26.36, which keeps valuation central to Dr. Reddy’s Laboratories Share Price News.
- ROE is 11.69% and ROCE is 13.75%, both above the same-industry medians in the sector snapshot.
- HSBC maintained a Buy view and raised its target price to Rs 1,525, according to recent news reports on Dr. Reddy’s Laboratories Stock News.
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories Ltd. operates in the Healthcare sector and the Pharmaceuticals & Drugs industry. Dr. Reddy’s Laboratories Share Price is followed closely because the company is part of a large listed universe and appears in both NSE and BSE market tracking. The latest revenue figure provided is Rs 8,697.8 crore for Sep 2026, while EPS stands at Rs 33.52 and book value at Rs 464.6 per share. Dr. Reddy’s Laboratories Stock Analysis is often read alongside Dr. Reddy’s Laboratories Financial Results, market cap and peer context. In Univest coverage, Dr. Reddy’s Laboratories Share Price is treated as a live market story within its sector and industry classification.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
Why is Dr. Reddy's Laboratories Share Price near a 52-week high?
Ans. Dr. Reddy's Laboratories Share Price is near Rs 1,389, which keeps it close to its yearly high. The move is small today, but the stock remains on watch because of its valuation, sector position and recent news flow.
What is Dr. Reddy's Laboratories Share Price Today?
Ans. Dr. Reddy's Laboratories Share Price Today is Rs 1,389, up 0.14% from the previous close of Rs 1,387. It moved between Rs 1,376.8 and Rs 1,390 during the morning trade.
What does Dr. Reddy's Laboratories Stock News show today?
Ans. Dr. Reddy's Laboratories Stock News includes HSBC maintaining a Buy view and raising its target price to Rs 1,525. The note also said 2QFY27 operational performance met expectations.
How is Dr. Reddy's Laboratories valued versus the industry?
Ans. Dr. Reddy's Laboratories Share Price trades at a P/E of 41.38 and P/B of 2.99. Both are above the same-industry medians of 26.36 and 2.73, respectively. The stock belongs to the Healthcare sector.
What are the key fundamental metrics for Dr. Reddy's Laboratories Share Price?
Ans. Key metrics include market capitalisation of Rs 1,15,267.47 crore, ROE of 11.69%, ROCE of 13.75%, EPS of Rs 33.52, book value of Rs 464.6 and dividend yield of 0.58%.
How does Dr. Reddy's Laboratories compare with peers?
Ans. Dr. Reddy's Laboratories Share Price has a P/E above Cipla, Zydus Lifesciences, Aurobindo Pharma and Lupin, but below Mankind Pharma. Its P/B is below several peers in the same industry group.
What sector does Dr. Reddy's Laboratories belong to?
Ans. Dr. Reddy's Laboratories belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. That sector context is central to Dr. Reddy's Laboratories Share Price and its peer comparison.
Where can I track Dr. Reddy's Laboratories Share Price live?
Ans. You can track Dr. Reddy's Laboratories Share Price on Univest for live price updates, market cap, valuation ratios, peer comparison, revenue context and stock news in one place.
Track Dr. Reddy’s Laboratories Share Price on Univest
Use Dr. Reddy's Laboratories Ltd. (DRREDDY) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Track Dr. Reddy’s Laboratories Share Price on Univest for live share price updates, key valuation ratios, sector comparison, market cap, revenue context and stock news. Readers can also follow Dr. Reddy’s Laboratories Share Price Today, company updates, peer positioning and the 52-week high range on one page.